๐Ÿ›๏ธ Verified NIH Record โ€ข Updated 2026-06-23

Improving the Care of Incontinence-Associated Dermatitis (IAD) Using a Beta-Glucan Cream as a Hydrating and Soothing Agent (NCT07524439)

๐ŸŸข Recruiting Observational / Diagnostic ๐Ÿ’Š Investigational Drug / Biologic Sponsor: University of Alberta

๐Ÿฉบ Plain-English Summary (8th-Grade Level)

The goal of this clinical trial is to determine whether adding a ฮฒ-glucan moisturizing cream to routine skin care can enhance skin healing, accelerate visible recovery, reduce discomfort, and improve both patient and clinician experiences. The study will also learn about the safety and tolerability of the ฮฒ-glucan cream when used along with standard skin care. The main questions it aims to answer are: Are there visible changes in the severity of IAD when ฮฒ-glucan cream is added to standard care, and if so, to what extent does it reduce severity compared with standard care alone? Does the ฮฒ-glucan cream help IAD heal faster? Does the cream reduce symptoms such as pain, itching, tingling, or burning? What medical problems or side effects, if any, do participants experience while using the ฮฒ-glucan cream? Researchers will compare standard care plus ฮฒ-glucan cream to standard care alone to see if the ฮฒ-glucan cream provides additional benefit for treating IAD. Participants will: Receive either ฮฒ-glucan cream plus standard care or standard care alone Have the study cream applied once daily for up to 2 weeks Have their skin checked weekly by the study team using a standardized assessment tool Answer questions about symptoms such as pain, itching, tingling, and burning Allow photographs of the affected skin area to be taken for secure clinical review Be monitored for any side effects or skin reactions during the study

Who can join: Review the eligibility criteria below.

Location: University of Alberta Hospital โ€” Edmonton, Alberta

Age range: 18 Years

๐Ÿงช Interventions in This Study

๐Ÿ“‹ "Do I Qualify?" โ€” 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria โ†—

๐Ÿ“ All Participating Trial Locations (1 Sites)

  • University of Alberta Hospital โ€” Edmonton, Alberta

๐Ÿ“ž Contact the Study Coordinator

Phone: (780) 263-6245

Email: eatang@ualberta.ca

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

๐Ÿ’ฐ Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

๐Ÿ’ก How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
๐Ÿ›๏ธ View Official NIH Record โ†—